EQS-News: CHEPLAPHARM expands Management with Tamás Szóga as VP Commercial
EQS-News: CHEPLAPHARM AG
/ Key word(s): Personnel
Werbung Werbung CHEPLAPHARM EXPANDS MANAGEMENT WITH TAMAS SZOGA AS VP COMMERCIAL
Greifswald, January 2, 2025 The globally active CHEPLAPHARM Group, headquartered in Greifswald, is continuing to position itself for the future and is expanding its management team. Tamás Szóga started as Vice President (VP) Commercial on 1 January 2025. The position was newly created. Tamás Szóga comes from Recordati Spa and takes over the Commercial division for the entire CHEPLAPHARM Group. Werbung Werbung
‘Maximisation of growth through strategic brand development and implementation of innovative commercial strategies will be the main tasks for Tamás Szóga. The newly created position of VP Commercial demonstrates the importance of this function within the company. I am therefore delighted that we have been able to recruit Tamás Szóga, a leader with two decades of expertise in the development of markets and product portfolios in the pharmaceutical industry,’ says Edeltraud Lafer, CEO of the CHEPLAPHARM Group. Werbung Werbung
About Tamás Szóga Tamás Szóga joins from Recordati Spa, where he has been responsible for portfolio development in 30 markets and Managing Director for the international business since the beginning of 2022. Prior to this, he was Director, Strategic Projects at EGIS focusing on global initiatives. He spent the longest part of his career at GlaxoSmithKline for 18 years across various geographies, where he held positions with increasing responsibility in portfolio development, commercial operations, market access and business development. Tamás Szóga started his career at management consultancies such as KPMG and Ernst & Young. Tamás Szóga holds an economist degree with finance and accountancy specification from Budapest Business University. CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For over 20 years, the company has been very successful in taking over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution. In this way, CHEPLAPHARM ensures the continuous supply of these medicines to patients worldwide. In addition to its headquarters in Greifswald, CHEPLAPHARM operates further sites in France, Japan, Russia and Switzerland. The company employs around 780 people worldwide.
Please refer to www.cheplapharm.com for additional information.
Press office: CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ press(at)cheplapharm.com
02.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Cheplapharm AG |
Ziegelhof 24 | |
17489 Greifswald | |
Germany | |
Phone: | 03834 3914 O |
E-mail: | info@cheplapharm.com |
Internet: | www.cheplapharm.com |
ISIN: | DE000CHP2222 |
WKN: | CHP222 |
EQS News ID: | 2059991 |
Notierung vorgesehen |
End of News | EQS News Service |
|
2059991 02.01.2025 CET/CEST
Nachrichten zu CHEPLAPHARM
Analysen zu CHEPLAPHARM
Keine Analysen gefunden.